A Perspective on Cardiac Disease and Regenerative Medicine {#S1}
==========================================================

Organ transplantation is one of the greatest medical achievements of the 20th century. However, its applicability is hampered by donor shortage, life-long immunosuppression and its success rates are linked to the experience of the surgical team. It requires a well-coordinated national effort, which is sometimes hindered by ethical issues ([@B221]). The search for novel ways to approach organ repair inspired the field of regenerative medicine, with Stem Cell Therapy as one of the most representative examples. Since this began, stem cells have been discovered even in low turnover adult tissues, such as the central nervous system ([@B59]), the lung, ([@B230]; [@B14]) or the heart, ([@B22]) and have been widely assayed in animal models of disease, quickly reaching clinical trials. This swift progression in general met with rapid failure, but on the bright side, it also enabled specialists to gain immense insights into their mechanisms and ways of action.

Nothing exemplifies this journey better than the cardiac field. Cardiovascular diseases are well recognised as the leading cause of death worldwide, accounting for almost 1 in 2 deaths in Europe and causing 3.9 million deaths per year ([@B268]). Ischemic heart disease (IHD) is one shade on this spectrum. It is generally caused by the clotting of a coronary vessel, which in turn leads to the death of a portion of the myocardium and the subsequent functional impairment of the organ. Being mostly non-regenerative, the heart is chronically impaired ([@B69]). A real epidemic, IHD is the leading single cause of death globally, responsible for over 15 million deaths in 2016, ranking first in high- and lower-middle-income countries, and third in low-income countries ([@B296]). As per 2015, over 22 million EU citizens were living with the disease, with approximately 3 million new cases yearly. IHD imposes an enormous burden on society as affected patients must be cared for by health systems, requiring lifelong highly specialised medical attention and multimedication. It also jeopardises the structure of the workforce and puts significant pressure on families. In terms of economic cost, the total burden of IHD for EU economies is estimated at €59 billion/year. Of these, €19 billion is directly related to healthcare costs, while €20 billion is linked to productivity losses and the remaining €20 billion to the cost of indirect care. Estimations sketch out a grim future. In the United States, heart attacks are projected to contribute more than \$818 billion to annual healthcare costs and lost productivity by 2030, ([@B199]) while in the South Asia region, direct medical costs for CVD are estimated to reach US \$16.6 billion in 2021 ([@B282]). Organ transplant cannot match this overwhelming demand and become a widespread therapeutic option ([@B254]).

It was hoped that cell therapy would provide new means to regenerate the scarred myocardium. Remarkable discoveries encouraged rapid progression towards clinical trials, with the first one launched in record time ([@B21]). After the BOOST and REPAIR-AMI trials reported significant benefits in cardiac function, ([@B293]; [@B238]) hundreds of patients were recruited often in individual efforts mostly based on local experience. This led to the first voicing of concerns. The primary initial objective, improvement of cardiac function, failed to be met in many cases. Although statistically significant benefits in cardiac function were sometimes found, their magnitude was not as great as had been expected (reviewed in [@B93]; [@B178]). This reversal of fortunes coincided also with a remarkable twist in our understanding of what basic science and animal models conveyed: no true regeneration of the myocardium was achieved by adult stem cells. The underlying effects were mostly due to the paracrine secretion of beneficial molecules ([@B106]). Although this general perspective is valid for most adult stem cells, use of their embryonic counterpart, although boosted by their capacity to give rise to new tissue once transplanted, was still marred by some common issues such as lack of proper engraftment, and crucially by safety concerns as teratoma formation and need for immune suppression, as well as ethical issues.

Did stem cell regenerative medicine approaches fail? They obviously did not achieve the initial aims, but looking back, those can no doubt be branded as overambitious ([@B209]). It did succeed in gathering a whole new compendium of knowledge, which has led to renewed and better efforts in the regenerative direction and, importantly, has built a worldwide network of excellence encompassing not only different nationalities, but also very diverse scientific disciplines. One of the greatest and perhaps now evident realisations in the field is the notion that cells are not alone in a tissue, and that the extracellular matrix (ECM) has a predominant role, not only as a passive architectural element, but crucially as a signal transducer and determinant of functionality ([@B166]; [@B52]; [@B148]). Specifically in the myocardium, the ECM is highly dynamic, changing during development and disease. This latter change is bidirectional, as disease induces pathological ECM deposition but an abnormal matrix is able to produce malfunction ([@B79]). In consequence, it is now recognised that a cell-based cardiac regeneration without an adequate ECM is not viable. Generating new myocardium thus requires the participation of the most promising cells, with a surrounding matrix able to replicate the conditions of the native tissue and the proper 3D architecture. This is precisely one of the main directions of cardiac Tissue Engineering.

Cardiac Tissue Engineering (cTE) is a highly interdisciplinary scientific discipline, aiming at reproducing as accurately as possible the function and biology of cardiac muscle, during development or maturity, health or disease. Although its first objective was focused on meeting the needs of cardiac regenerative Medicine, as knowledge and experience on how the ECM influences cardiac cell biology increased and the fabrication capacities widened, its scope has greatly expanded into areas such as disease modelling, drug testing and personalised medicine amongst others ([@B73]; [@B198]; [@B171]). This review aims at presenting the reader with an overview of the specific characteristics of the myocardium that determine the needs regenerative cTE has to meet, as well as providing a non-exhaustive revision of what the field has delivered to attain this end, with a focus on human myocardium and human pluripotent stem cells.

The Heart {#S2}
=========

The mammalian heart is an incredible organ. Its main role is to provide a continuous unidirectional supply of blood to the organism. This comes at a stringent metabolic cost, consuming the equivalent of 6 kg of ATP per day, with a complete renewal of its ATP pool every 10 seconds. Most of this energy is obtained through the oxidation of fatty acids in adulthood, though cardiac metabolism is dependent on glucose during embryonic stages, being able to employ lactate as a metabolic substrate ([@B196]). Correct function is achieved through a specialised organ architecture, dividing the heart into 4 chambers: atria, which are smaller in size and muscular mass, receive blood and push it out into the ventricles, which in turn pump either towards the lungs or the body. In consequence, the left ventricle is larger and has a thicker muscular wall than its right counterpart. Chambers, inlets and outlets are separated by valves impeding back flow. The heart is the first organ to function, around day 8 in mice and the 4^th^ gestational week in humans ([@B30]). It pumps continuously throughout life, efficiently ejecting blood through an exquisite 3D structure, ([@B34]) established by a complex set of embryonic movements, cellular growth and incorporation ([@B91]). Disruption of this structure is seen in disease and can be in itself the cause of organ malfunction: cardiac congenital defects and malformation are a main cause of perinatal death, ([@B31]) but also give rise to many cardiomyopathies ([@B174]).

Cardiac Embryonic Development: A Brief Overview {#S2.SS1}
-----------------------------------------------

The formation of the mammalian four-chambered heart encompasses a series of tightly coordinated morphological, cellular and molecular events (reviewed in [@B277]; [@B176]; [@B234]). Different pools of cardiac and extracardiac progenitors are involved, including the mesoderm-derived First, Second and Third Heart Fields (FHF, SHF and THF respectively) and the Cardiac Neural Crest Cells (CNCCs). Cells of the FHF contribute primarily to the left ventricle (LV) but there is also a small contribution to the atria; SHF will form the right ventricle (RV), outflow tract (OFT), atria and part of inflow tract (IFT); ([@B37]). THF cells contribute to the sinus node, some regions in the caval myocardium, and the Pro-Epicardial Organ (PEO) ([@B188]; [@B31]). CNCCs arise from the dorsal neural tube, contribute to the parasympathetic innervation of the heart, valves and play a pivotal role in OFT patterning and optimal septation ([@B135]).

Early precardiac progenitors from the lateral mesoderm have been mapped into the mid-anterior region of the primitive streak, characterised by the presence of both anterior Nodal/Activin and posterior bone morphogenetic protein (BMP) signalling at low levels, ([@B314]; [@B275]; [@B299]; [@B305]) promoting the emergence of cardiogenic mesodermal MIXL1 + KDR + cells. As a result of these signalling gradients set in gastrulation, multipotent cardiovascular progenitor (M) expressing the cardiac master regulator MESP1 move in an anterior-lateral direction, forming a horseshoe-like region termed the cardiac crescent or FHF ([@B29]; [@B47]). At a molecular level, MESP1 induces the expression of the minimal core of the essential cardiogenic transcription factors including ISL1, TBX5, NKX2.5, and GATA4, in combination with the chromatin remodeller SMARCD3 (BAF60C), which further drive cardiomyogenesis ([@B277]; [@B176]; [@B175]). The cardiac crescent fuses at the midline, forming the linear heart tube, which consists of an interior layer of endocardial cells and an exterior layer of myocardial cells separated by an acellular, ECM-rich space, the cardiac jelly. Located central and dorsal to the FHF, SHF cells remain in contact with the pharyngeal endoderm and in a proliferative state as undifferentiated ISL1 + MEF2C + cells. As development proceeds, SHF cells are added to the poles of the heart tube, with the tube looping to position the different regions into place. Chambers balloon out as a result of the differential proliferation rates of CMs ([@B123]; [@B50]). As already mentioned, THF cells (TBX18 + NKX2.5-) contribute to the sinus node, caval myocardial cells and the PEO. PEO-cells give rise to the epicardium, and some cells of this layer undergo epithelial-to-mesenchymal transition to form epicardial derived cells (EPDC), which will differentiate into vascular cells (including the coronaries) as well as interstitial fibroblasts and valvular cells, being essential for compaction ([@B217]; [@B288]; [@B131]). Lastly, CNCCs originate by delamination from the neuroectoderm, ([@B102]) initially contributing to smooth muscle cells and CMs, ([@B185]) and making a significant contribution to the innervation of the organ and to the OFT ([@B102]; [@B249]). We refer the reader to [Table 1](#T1){ref-type="table"} for a full description of the mentioned gene abbreviations.

###### 

Full description of genes names.

  Abbreviation   Description
  -------------- ---------------------------------------------------------------------------------------------------
  MIXL1          Mix Paired-Like Homeobox
  KDR            Kinase Insert Domain Receptor
  MESP1          Mesoderm Posterior BHLH Transcription Factor 1
  ISL1           Islet-1 LIM Homeobox
  TBX5           T-Box Transcription Factor 5
  NKX2.5         NK2 homeobox 5
  GATA4          GATA Binding Protein 4
  SMARCD3        SWI/SNF Related, Matrix Associated, Actin Dependent Regulator Of Chromatin, Subfamily D, Member 3
  BX18           T-Box Transcription Factor 18

Post-birth Cardiac Development: Foetal CMs vs. Adult CMs {#S2.SS2}
--------------------------------------------------------

Aside from the formation of the mammalian heart, CMs continue to develop postnatally ([@B92]). Embryonic CMs can beat spontaneously, express sarcomeric proteins and ion channels, and exhibit action potentials and calcium transients which are significantly distinctive from their adult counterpart ([@B277]; [@B176]). Human and rodent embryonic CMs are around 30-40 fold less in size and feature an irregular shape, in comparison with adult CMs ([@B301]). These are characterised by an ultrastructural organisation with a large mitochondrial volume and specific mitochondria positioning between myofibrils. Sarcomeres in postnatal CMs are long and well-aligned, in contrast to shorter and disarrayed ones found in foetal CM. At a metabolic level, embryonic CMs rely on glycolysis, whereas adult myocytes preferentially consume fatty acids, a much more efficient energy source. Myofibrillar protein isoform undergoes switching, being myosin heavy chain 7 (MYH7), myosin light chain 2 ventricular isoform (MLC2v), cardiac troponin I3 (TNNI3) and a shorter and stiffer Titin isoform, preferentially expressed in adult CMs, in contrast to myosin heavy chain 6 (MYH6), myosin light chain 2 atrial isoform (MLC2a), and slow skeletal-type troponin I1 (TNNI1) on foetal CMs ([@B20]). All these differences directly correlate with contractile capacity, with adult CMs able to generate more force than embryonic ones ([@B277]; [@B176]; [@B261]). For example, strips of adult rat myocardium have been reported to produce a peak twitch tension of 56.4 ± 44 mN/mm2, ([@B97]) whereas collagen constructs with neonatal rat CMs generated 0.4-0.8 mN/mm2 ([@B322]). The same difference in magnitude is believed to exist for human cells, as comparisons with primary foetal human CMs are rare ([@B301]).

The cardiac action potential and associated channels and currents also distinguishes adult and foetal CMs. In immature CMs, the expression of channels involved in repolarisation, including potassium transient outward channels, L-type calcium currents and the rectifying K + current (encoded mainly by KCNJ2), is lower than in adult cells resulting in a less negative resting membrane potential (−50mv ∼−60 mv in embryonic CMs) compared to normal (--85mv ∼ --90 mv in adult CMs) ([@B311]). Also, the pacemaker current I~f~ is present in embryonic CMs but does not occur in adult myocytes ([@B235]). The distribution of the gap junction protein connexin 43 (Cx43) also plays an important role in regulating electrical activity. While Cx43 concentrates at the intercalated disc of adult CMs, it is circumferentially distributed in immature CMs, which is not optimal for longitudinal electrical propagation ([@B279]; [@B121]). Adult CMs have a well-developed sarcoplasmic reticulum (SR) with a high level of SR-specific proteins like ryanodine receptor 2 (RYR2) and sarcoplasmic/endoplasmic reticulum Ca2 + ATPase 2a (SERCA2), ([@B111]) which, coupled with the presence of transverse tubules (t-tubules), leads to a highly coordinated Ca-induced-Ca-release and hence faster Ca transient kinetics and amplitude when compared to foetal CMs ([@B160]). Finally, where embryonic CMs are diploid, adult CMs present different degrees of polyploidy, achieved through DNA-synthesis without karyokinesis ([@B2]; [@B99]). Understanding how an embryonic CM evolves into a mature cell is already proving fundamental in human cTE. As the bioartificial tissues developed so far resemble more their foetal counterpart, this insight is being incorporated into the effort of driving engineered tissues towards an adult-like functionality ([@B128]).

Heart Characteristics: What We Aim to Engineer {#S2.SS3}
----------------------------------------------

Generating human myocardial surrogates in the laboratory requires knowing what the natural composition and properties of the organ are. The following paragraphs provide an overview of what nature has achieved, specifically, what the main cellular and extracellular components of the heart are, how they are arranged in space, and importantly, what this means regarding the resulting material properties ([Figure 1](#F1){ref-type="fig"}).

![Main components of the mammalian heart. The two main constituents of the myocardium, cardiac cells and the surrounding ECM, both contribute to and modulate the specific material properties of the tissue.](fbioe-08-00955-g001){#F1}

### Cellular Composition {#S2.SS3.SSS1}

As already explained, most cells forming the structure of the heart are of mesodermal origin: CMs, vascular (endothelial and smooth muscle) cells and fibroblasts. Others reside in the tissue but are formed elsewhere, as immune cells, which play a significant role in organ surveillance and disease. Deciphering the cellular composition of the heart has been a very controversial subject, be it in rodents or humans ([@B318]). Histology can determine that CMs are the largest fraction by volume. However, numbers vary, with reports of murine myocytes being the largest population by number \[56/27/7 for CMs/fibroblasts/endothelial cells respectively ([@B11])\] and others attributing greater numbers to endothelial cells \[43.6% vs 31% of CMs ([@B218])\]. Human proportions are similarly contradictory, with some publications showing non-CM/endothelial cells are the most abundant ([@B24]) and others endothelial cells ([@B6]). Furthermore, several studies have reported varying cell proportions throughout the anatomical regions of the organ ([@B257]; [@B83]; [@B44], [@B43]; [@B145]; [@B19]). Things become more complicated if we take into account the age of the individual, as some claim the final number of myocytes is reached by one month, remaining constant over the lifetime of the individual ([@B24]) whereas others have reported a 3.4-fold increase in CM number between 1 and 20 years of age ([@B187]). Other cell type numbers change dynamically over time, with a reported 6.5-fold increase in endothelial cells and an 8.2-fold increase for mesenchymal cells (including fibroblasts) during heart growth. Interactions between these cells are multidirectional and exert great influence over crucial aspects of cardiac biology. Both endothelial cells and fibroblasts are key for tissue function and homeostasis. Aside from delivering oxygen and nutrients to the metabolically demanding CMs, the endothelium is fundamental for tissue hypertrophy and post-disease remodelling, ([@B108]) and maturation, ([@B86]) displaying a strong paracrine influence (reviewed in [@B154]). Fibroblasts also affect organ function and cell maturity, ([@B294]; [@B283]) whilst other cell types, such as immune cells, have been reported to display direct and significant interactions with CMs, as is the case with the electrical coupling of macrophages with atrioventricular node cells ([@B110]). All in all, the general consensus supported by unambiguous histological evidence is that CMs are the largest fraction by volume, each nurtured by a median of 3 capillaries, where fibroblasts constantly keep the ECM through a degradation-deposition equilibrium. This brings us to our next player: the cardiac ECM.

### ECM Composition {#S2.SS3.SSS2}

The cardiac cell types discussed above are arranged within a glycoprotein matrix which supports and provides them with a structure. Moreover, the cardiac ECM also has an active role in transmitting contraction and avoiding hyper-stretching of CMs. Its principal component is collagen, which accounts for 2--5% of the total weight of the heart, mainly types I (89%) and III (11%). Collagen type IV is present in the basement membranes, and collagen type V is located in the pericellular space ([@B286]; [@B66]; [@B251]). The collagen matrix has classically been categorised depending on which elements it tethers together into endomysium (binds adjoining CMs), perimysium (aggregates myocytes into myofibrils) and epimysium (present at the epicardial and endocardial surfaces). Cardiac fibroblasts have been identified as the main cell type responsible for secreting and remodelling the collagen matrix, although CMs seem to contribute to collagen type IV deposition ([@B65]). Apart from the structural function, the collagen network makes an important contribution to the whole myocardial tensile properties ([@B77]).

Another key element of the cardiac extracellular matrix is elastic fibres. These are composites, made of an elastin core surrounded by a myriad of microfibrils. They provide elastic properties, by stretching upon mechanical demand and going back to their original length once the load is removed. Hence the importance of elastic fibres in tissues which have to accommodate their structure, such as skin, arteries or lungs or the heart. However, although elastic fibres are paramount for the heart's elasticity, other factors are known to have an influence upon it, namely the proportion of muscle bundles to fibrotic tissue, and the density of collagen crosslinking ([@B78]; [@B213]). In fact, elastic fibres are found in most cases close to the collagenous network and in intimate association with it ([@B236]). Of note, mature elastic fibres show slight architectural differences depending on the tissue ([@B139]). As aforementioned, elastin forms the core of elastic fibres. Unlike most matrix proteins, which undergo a constant/continuous deposition and turnover, in healthy conditions elastin is synthesised only until adolescence ([@B63]; [@B39]; [@B57]; [@B193]; [@B241]; [@B212]; [@B219]; [@B227]). Other fundamental components of the cardiac matrix include, to a lesser extent, laminin, fibronectin, proteoglycans and glycoproteins ([@B71]). Laminin molecules are part of the basement membrane and are thus in close contact with the cell, playing an active role in modulating cell behaviour, including migration, differentiation and phenotype stabilisation ([@B302]). Fibronectin, besides promoting cell attachment, acts as an ECM organiser and is involved in collagen deposition ([@B274]). However, all components are crucial for tissue integrity and function.

Many, if not all, cardiovascular diseases have repercussions for the cardiac ECM. The reverse is also true. For instance, infarction studies in pigs show that the collagenous network starts to become disarranged after just 20 min of coronary occlusion, whilst elastin begins to disappear after 40 min, and both components appear detached from the basement membrane after 120 min. The balance of collagens I and III has been widely studied, revealing a significant increase in type III collagen after myocardial infarction (MI) ([@B236]). Dilated cardiomyopathies, in which the shape of the cardiac cavity is abnormal, are at least partly related to aberrant collagen remodelling, with less thick collagen and thinner fibres, which results in weaker tensile properties, more muscle slippage and wall thinning ([@B287]; [@B286]). Ventricular hypertrophy consists of the thickening of the ventricular wall associated with some conditions like hypertension, and it is found together with overexpression of collagen in the form of interstitial fibrosis ([@B66]).

### Cardiac Architecture {#S2.SS3.SSS3}

In most tissues, structure and function are closely intertwined, and the heart is no exception. However, certain aspects of this relationship are still under debate. The overall manner in which the heart contracts and pumps blood is known, as is the arrangement of the tissue microstructure. The gap lies in providing a theory that explains how the different architectural elements interact to produce the global behaviour. For example, there is an ongoing debate about whether the myocardium forms a single myocardial band, ([@B35], [@B36]) or the so-called myocardial mesh model is more accurate ([@B162], [@B163]). The controversy has two aspects. On the one hand, there is no consensus on whether the basic functional unit is the CM, or groupings of this into bundles (groups of CMs), sheetlets (groups of bundles), sheets (groups of sheetlets) or even laminae (groups of sheets). On the other hand, although imaging techniques allow us to visualise phenomena across the whole myocardium, it is not feasible to ascertain the distinct contribution of the individual functional units to producing the global outcome. According to Buckberg et al., the CM can undergo six functional events: shortening, lengthening, narrowing, widening, twisting and uncoiling ([@B35], [@B33]). There are an estimated 2.5-10 billion cells ([@B24]) in the heart, each of them performing one or more of these six actions in the same or a different direction, and all we are able to see is the macroscopic effect: a torsion-contraction movement of the organ. Still under controversy, there are at least 7 proposed models to accurately describe cardiac architecture, ([@B88]) which is widely recognised to have a profound effect, whether at a mechanical ([@B153]; [@B323]) or electrical ([@B228]; [@B258]) level. During disease, myocardial architecture is severely disarranged, leading to inefficient contraction ([@B229]; [@B291]). It is expected that the application of advanced technology like diffusion tensor MRI (DT-MRI), which can obtain highly detailed information on fibre architecture, will soon shed light on this debate ([@B239]; [@B220]).

At a simpler histological level, CMs (and CM bundles/sheetlets) are arranged in different orientations depending on their location in the organ, which in turn determines the direction of the stress produced. Myocytes are always in intimate contact with capillaries, which no doubt stems from the high metabolic demand of an ever-working muscular tissue: capillaries are located within 20 μm of CMs. Each CM is surrounded by a basement membrane containing laminin and collagen type IV, amongst others, and embedded in a highly structured ECM where collagen type I, as already discussed, is the main component ([Figure 2](#F2){ref-type="fig"}). CMs connect to each other mainly by intercalated disks at their ends, but also through side branches, coupled to at least 2 CMs on the long axis and 1 laterally ([@B253]). Intercalated disks contain gap junctions, allowing fast current flow between neighbouring cells ([@B143]). As mentioned above, both individual CMs and groupings of these are surrounded by enveloping collagen. Fibroblasts do not participate in the electrical syncytium formed by the CMs, but rather lie in the interstitial space.

![Cardiac structure. The endocardial-to-pericardial structure is outlined, with the main cellular and extracellular components.](fbioe-08-00955-g002){#F2}

### Cardiac Biophysical Properties {#S2.SS3.SSS4}

When attempting to engineer a tissue, it is essential to carefully recapitulate not only the cellular-extracellular components and their architecture, but also the resulting biophysical properties. These must reliably mimic those of their natural counterpart. In the heart, material properties are very complex: not only are they direction-dependent, but they also vary within the anatomical regions and the stage of the cardiac cycle. As an example, the literature reports variations in stiffness between the beginning and the end of diastole higher than an order of magnitude. For human LV, the reported values are 10-20 kPa at the beginning of the diastole, and 200-500 kPa at the end ([@B49]). Contraction itself results in a significant stiffening: from 0.5 to \> 10 kPa. This magnitude is species-dependent, with a reported 3-fold increase in mouse, ([@B116]) 2-fold in rat, ([@B222]) and over 20 times in zebrafish ([@B147]). Development also leads to a stiffening in the tissue, which arises from a relatively soft mesodermal layer ([@B147]). Disease severely stiffens the organ, mostly due to the excessive deposition of collagen (scar for MI, interstitial in hypertension or other conditions), with values of over 50-100 kPa ([@B68]). Stiffness itself has a fundamental influence on how efficient CM contraction is, with CMs on softer- or stiffer-than-normal substrates doing little work or overstraining themselves, respectively ([@B68]). Reports on cardiac mechanical properties are extremely variable. This stems from a mix-up of animal vs human, fresh vs fixed, and healthy vs diseased data. In general, it is now accepted that most of the heart's passive mechanical properties are due to the collagen in the matrix, ([@B251]) but at short sarcomere lengths the protein titin is the predominant contributor ([@B197]). Quoting Sommer et al., 'results suggest that the passive human LV myocardium under quasi-static and dynamic multiaxial loadings is a non-linear, anisotropic (orthotropic), viscoelastic and history-dependent soft biological material undergoing large deformations' ([@B252]). Or in simpler words: it is very complex and with multiple contributions from cellular/extracellular components. Added to this, scales differ, depending whether the tissue is macroscopically characterised using biaxial mechanical tests, ([@B252]) or whether isolated CMs are probed at a cell-relevant scale with Atomic Force Microscopy (AFM) ([@B5]). Furthermore, some conflicting results have been reported, from reports showing force production from CMs to be increased with increasing stiffness, ([@B26]) to stiffness having no influence at all ([@B117]). In fact and as explained by [@B60], it might even be the case that the material properties of cardiac tissue are not the main actor in the myocardial scenario, but this role is rather played by chamber pressure. More experimental and theoretical work needs to be done in this area before we reach a definitive conclusion.

Adding another layer of complexity, the heart has constant, potent and highly relevant electrical activity. Sparking at a small and specialised region called the sinoatrial node, the electrical wave travels through the auricles, reaching the atrioventricular node where it is delayed (allowing for the filling of the ventricles), and then spreads apex-to-base through the ventricles in a coordinated manner. All this process is controlled by a singular CM type, termed pacemaker cell, displaying disarrayed sarcomeres and low work generation capacity, but able to autonomously start the cardiac action potential. Ultimately, the action potential results in the entry of Ca^+2^ ions into the CM, releasing the sarcoplasmic stores of Ca^+2^ and freeing myosin of the inhibitory action of troponin I. CMs are also electrically connected through connexins, which form bridges between the cytoplasm of adjacent myocytes, effectively making the myocardium an electrical syncytium. However, it is an anisotropic one, with faster propagation in the direction of the fibres as opposed to the transverse direction ([@B51]). Conduction velocity is the speed with which the cardiac impulse travels from one point in the tissue to another. In adulthood, it lies in the range of 0.3-1 m/s, but developmental stage and disease will affect it ([@B301]). Achieving a similar value in any cardiac engineered tissue is paramount, given the fact that a mismatch between conduction velocities may give rise to potentially fatal electrical abnormalities such as arrhythmias ([@B125]; [@B312]). It is interesting that one of the foci in cTE is towards providing material-based electronic conductivity, although cardiac cells do not function by transmitting electrons but ions.

As mentioned already, both the mechanical and electrical properties exert a strong influence upon myocardial biology and function, in both health and disease. For example, increased fibrosis due to pathological conditions like MI or hypertension significantly stiffens cardiac muscle and affects CM contraction ([@B244]). Ventricle loading induces CM elongation which, as explained by the Frank-Starling law, renders higher stroke with increase diastolic filling ([@B250]). The coordinated conduction of the depolarisation wave throughout the organ, including the atrioventricular delay and the apex-to-base transmission, all contribute to optimal functionality and must be taken into account when engineering a human myocardium.

Engineering Cardiac Tissue: The Building Blocks {#S3}
===============================================

cTE aims to generate tissue surrogates, either micro or macro, for various purposes, from developmental biology, ([@B303]) to therapy ([@B184]). In the following paragraphs, we will outline the main cells and materials, as well as the different fabrication technologies assayed in the field and the procedures for their maturation. [Table 2](#T2){ref-type="table"} summarises some of the most relevant engineered myocardium examples, with a focus on human cardiac tissue.

###### 

Summary of materials, cells and methods employed to engineer cardiac tissues, their biomimicry and resulting outcome.

  REF       Materials       Fabrication     Cellular mimicry   Material mimicry   Maturation   Benefit of the selected approach?                                                  
  --------- --------------- --------------- ------------------ ------------------ ------------ ----------------------------------- ---- ---- ---- ----- ---- ---- ----- ---- ---- ----
  [@B89]    Col I           --              Mould casting      Rat neonatal       Yes          No                                  No   \+   \+   NM    nd   \+   \+              
  [@B104]   Fibrin          .               Mould casting      Rat neonatal       Yes          No                                  No   \+   \+   EHT   \+   \+   \+              
  [@B115]   FGN             --              Mould casting      Rat neonatal       Yes          No                                  No   \+   --   NM    \+   \+   \+              
  [@B4]     Albumin         --              Mould casting      Rat neonatal       Yes          No                                  No   --   --   2D    \+   \+   --              
  [@B200]   Col I           --              Mould casting      hPSC                                                                     \+   --   --    --   \+   NM    \+   \+   \+
  [@B233]   Col I           --              Mould casting      hPSC                                                                     \+   --   --    \+   \+   EHT   \+   \+   \+
  [@B266]   Col I           --              Mould casting      hPSC                                                                FK   \+   --   --    \+   --   2D    nd   \+   \+
  [@B276]   Col I + ELN     --              Mould casting      hPSC                                                                FK   \+   --   --    \+   \+   2D    nd   \+   \+
  [@B308]   Fibrin          --              Mould casting      hPSC                                                                     nd   --   --    --   --   2D    \+   \+   \+
  [@B104]   Fibrin          .               Mould casting      hPSC                                                                     \+   --   --    \+   \+   EHT   \+   \+   \+
  [@B289]   Fibrin          --              Mould casting      hPSC               hPSC                                                  \+   --   --    \+   --   NM    nd   --   --
  [@B271]   Fibrin          --              Mould casting      hPSC                                                                     \+   --   --    \+   --   2D    --   \+   nd
  [@B231]   Fibrin          --              Mould casting      hPSC                                                                DF   \+   --   --    \+   \+   2D    \+   nd   nd
  [@B114]   FGN             --              Mould casting      hPSC                                                                     \+   --   --    \+   --   NM    nd   \+   \+
  [@B245]   FGN             --              Mould casting      hPSC               hPSC         hPSC                                     \+   --   --    \+   --   NM    \+   --   \+
  [@B56]    PVA\*           --              Foaming + FD       hPSC                                                                     \+   --   --    --   --   2D    nd   --   nd
  [@B95]    --              PCL             SE                 hPSC                                                                     --   --   \+    --   --   2D    \+   \+   --
  [@B122]   --              Col I           SE                 hPSC                                                                     \+   --   --    --   --   NM    nd   \+   \+
  [@B248]   --              POCS--FGN       SE                 hCM                                                                      \+   --   --    --   --   2D    nd   \+   nd
  [@B136]   --              PLGA            SE                 hPSC                                                                     --   --   \+    --   --   2D    --   \+   --
  [@B232]   --              Col I/HA/PANi   SE                 hPSC                                                                     \+   \+   --    --   --   EHT   nd   \+   \+
  [@B164]   --              PCL/Gelat       Pull spinning      hPSC                                                                     \+   --   \+    --   --   2D    nd   \+   \+
  [@B46]    Col I           PCL             MEW                hPSC                                                                     --   --   --    --   --   2D    \+   \+   nd
  [@B273]   PETra + MWCNT   3DP--SLA        hPSC                                                                                   No   \+   \+   --    --   2D   nd    \+   nd   
  [@B152]   Col I           --              3DbioP             hPSC                                                                CF   \+   --   --    --   --   NM    nd   \+   --
  [@B165]   FGN/PEG         --              3DbioP             hPSC               HUVEC                                                 nd   --   --    --   --   EHT   nd   \+   nd
  [@B198]   dECM            --              3DbioP             hPSC               hPSC                                                  \+   --   --    --   --   NM    nd   \+   \+
  [@B7]     --              --              3DbioP             hPSC               HUVEC                                            DF   nd   --   --    --   --   EHT   nd   \+   nd

REF, Reference; CM, Cardiomyocyte; EC, Endothelial cell; SMC, Smooth muscle cell; CF, Cardiac fibroblast; Mech, mechanical; Elec, electrical; Gene exp., Gene expression; Col I, collagen type I; FGN, Fibrinogen; hPSC, human pluripotent stem cell; FK, Foreskin fibroblast; DF, Dermal fibroblast; PVA, poly-vinil-alcohol; FD, Freeze-drying;

∗

, foam; SE, Solution electrospinning; POCS, poly\[1,8-octanediol-co-(citric acid)-co-(sebacic acid)\]; hCM, primary human CM; PLGA, polylactide-co-glycolide; PCL, polycaprolactone; Gelat, Gelatin; PETrA, pentaerythritol triacrylate; MWCNT, Multi-walled carbon nanotubes; 3DP,3D Printing; SLA, Stereolithography; PEG, polyethylene glycol; ALG, Alginate; 3DbioP, 3D bioprinting; nd, not described; dECM, decellularised extracellular matrix; ELN, elastin; HA, Hyaluronic acid; PANi, polyaniline; NM, native myocardium; EHT, engineered heart tissue.

Cells {#S3.SS1}
-----

The capacity to obtain human cardiac cell phenotypes in the laboratory began with the derivation of human embryonic stem cells (hESC) by Thomson and colleagues in 1998, ([@B264]) which was soon followed by the first protocols for differentiation towards CMs ([@B192]; [@B129]). In 2006, thanks to the breakthrough of the reprogramming technology ([@B259]; [@B304]) it became possible to relieve the field of some of its most notorious encumbrances, including the ethical ones. Both, hESCs and human induced pluripotent stem cells (hiPSC) fall within the wider category of human pluripotent stem cells (hPSC). Current methods, including scaling up protocols, ([@B243]) have paved the way for their widespread use. In general direct, efficient and reproducible hPSCs differentiation methods try to recapitulate embryonic development, from the induction of cardiac mesoderm, to CM, endothelial cells (ECs), cardiac fibroblast (CFs) or smooth muscle cells (SMCs) *in vitro* specification and maturation ([Figure 3](#F3){ref-type="fig"}) ([@B42]).

![Cardiac differentiation of hPSC. hPSC differentiation *in vitro* mimics embryonic development. Induction signals, main molecular pathways and lineage markers are outlined.](fbioe-08-00955-g003){#F3}

According to the culture format employed, derivation of CMs, CFs, ECs and pericytes/SMCs from hPSCs can be categorised into 3 main approaches: (i) inductive co-culture with visceral endodermal-like cells, (ii) suspension aggregates such as three dimensional (3D) embryoid bodies (EBs) and (iii) two-dimensional (2D) cell monolayer differentiation ([@B192]; [@B129]; [@B149]; [@B190]). Early reports showed that co-culturing hPSCs with the mouse endodermal cell line END2 was able to induce beating foci ([@B162]). The low efficiency of this method, as well as the need for xenogenic co-culture, precluded its widespread application. EBs are formed by culturing dissociated hPSC in non-adherent plastic dishes and partially recapitulate the 3D structure and interactions of a developing embryo. hESC-EBs differentiate to derivatives of the three primary germ layers, resulting in spontaneously contracting outgrowths of human CM ([@B134]). Based on EB differentiation protocols, CM from a variety of hESC and hiPSC lines have been generated, usually with a purity of \< 10% ([@B311]). ECs can also be isolated from spontaneously differentiating EBs, at a similarly low yield (≈2%) ([@B155]). In both cases, early reports explored the addition of cardiac mesoderm-inducing growth factors, including FGF2, VEGF BMP4, Activin A, Wnt agonists (WNT3A) or antagonists (DKK1), amongst others ([@B306]; [@B129], [@B130]; [@B300]; [@B269]; [@B118]). In general, however, EB-based differentiations have lost ground to more advanced and defined procedures, as the former are generally inefficient and render a mixture of cardiac cells with other non-cardiac phenotypes, requiring additional purification.

Monolayer-based differentiation is nowadays the most usually applied method. Cytokine-based protocols were developed first ([@B258]). These have been progressively modified by the discovery of Wnt signals playing a biphasic role in cardiac differentiation *in vivo*, ([@B168]; [@B270]) with early signals directing hPSCs towards cardiac fate, whilst later inhibition of those signals is a prerequisite for CM specification. Almost 10 years ago, this concept was incorporated into the CM differentiation from hPSCs, ([@B156]) paving the way for the grounding of a chemically defined procedure ([@B41]). Based on small molecules rather than cytokines, and thus less costly, this protocol is now widely applied, providing highly pure yields of hPSC-derived CMs when in combination with a metabolic-based selection ([@B267]). This means that complicated and inefficient EB-forming procedures or expensive and time-consuming immune-selection protocols have now been discarded ([@B40]; [@B98]; [@B67]; [@B272]). However, even this latest protocol still requires a degree of set up to avoid inconsistent efficiencies amongst cell lines and experimental repeats, mostly related to different patterns of endogenous early canonical Wnt expression ([@B210]). In general, CMs obtained from these protocols consist of a mixture of pacemaker, atrial and ventricular myocytes, though some researchers consider that this is open to question, as hPSC-CMs are immature and intrinsically plastic ([@B61]).

The derivation of other cardiac phenotypes has been also achieved, with a variety of protocols now available. Palpant et al. reported the generation of CMs, cardiac- or hemogenic-derived ECs as well as blood cells by finely dosing BMP4 and Activin A in order to pattern hPSC towards different mesodermal fates ([@B211]). Others have employed a mixture of small molecules and cytokines to derive vascular cells from hPSCs in monolayer culture with high efficiency ([@B206]; [@B215]). Global gene transcription analysis has demonstrated low variability between ECs differentiated via cytokine-based methods from multiple lines of hPSCs ([@B290]). CFs, have been increasingly recognised as major players in cardiac development and homeostasis, having a similarly significant effect upon the capacity to build cardiac tissues in the lab. Recently, two independent groups have reported the generation of hPSC-derived CFs, giving also proof of their capacity to affect hPSC-CM function ([@B309]; [@B310]). Epicardial cells have similarly been derived, ([@B292]) demonstrating their ability to increase the therapeutic capacity of hPSC-CMs *in vivo* ([@B13]). Finally, sinoatrial node pacemaker CMs have been obtained from hPSC, and their capacity to pace tissues *in vivo* has been reported ([@B223]). Other approaches to the differentiation of cardiac lineages include the generation of CVPs, ([@B28]; [@B27]; [@B315]) or direct reprogramming strategies, ([@B186]) but they have rarely been explored in cTE.

Materials {#S3.SS2}
---------

In parallel to the way differentiation of hPSC mimics the natural embryonic development, the current view is that the more a material replicates the properties of cardiac tissue, the higher the chances of success. Development over the last 15 years has yielded a wide portfolio of materials and biomaterials. Classifications are numerous, be it by origin (natural, synthetic or hybrid), crosslinking (chemical vs physical), size (macro, micro or nano), polymerisation mechanism (enzymatic, light-triggered or pH-responsive) or whether they are or not reinforced with other structures like fibres. For specific insight into these classifications, we direct the reader towards some of the excellent latest papers ([@B216]; [@B159]; [@B298]). One of the most relevant classifications is, however, on the physical consistency of the applied material, where we can differentiate (i) injectable materials and hydrogels, (ii) solid or fibrous scaffolds and (iii) composite systems.

Hydrogels are probably the most widely explored type of material in cTE. Collagen, being the main component of the cardiac ECM, has been widely employed (see the following sections). It can be readily isolated from animal or even human tissues in sufficient quantities, extracted and solubilised, although it requires acidic pH for this. Therefore, a careful control over pH is needed for optimal polymerisation and embedded cell survival. Gelatin, being denatured/digested collagen, has also been intensely explored and the basis for the generation of some of the most applied semi-synthetic materials, such as gelatin methacryloyl (GelMA)([@B307]) and several biorthogonal derivatives ([@B146]; [@B25]). Alginate, a sugar-based natural hydrogel obtained from algae, ([@B205]) has been employed due to their tailorable mechanical properties and simple polymerisation, mediated by cations such as Ca or Mg, albeit lacking biological binding motifs. Silk and its derivatives have also been processed into hydrogels, ([@B107]) and modified to incorporate electrically active particles ([@B15]) or photocrosslinkable chemical groups ([@B53]). Allergic and anti-inflammatory side reactions have been reported with some silk derivatives, so care should be taken when incorporating them into an engineered tissue. Amongst natural hydrogels, decellularised ECM (dECM) has attracted significant interest since the breakthrough discovery of the process, as applied to the building of tissues ([@B207]; [@B23]). In principle, dECM retains all components of the ECM of origin, thus creating a more complex and biomimetic environment. Garreta et al. obtained human dECM slices on which they cultured hPSC-CMs. The human CMs demonstrated enhanced conduction velocity and gene expression of related genes (SERCA, KCNJ2, CACNA1C or SCN5A amongst others) ([@B82]). The group of Lior Gepstein employed dECM-chitosan mixtures in combination with hiPSC-CMs. The resulting engineered myocardium displayed enhanced maturity as compared with cells cultured in 2D, showing tissue-like drug responses. Their work also provided proof-of-concept of the capacity of this system to model human cardiac diseases (Long QT syndrome) and arrhythmias ([@B90]). On the synthetic side, polyethylene glycol (PEG) and its several modifications have been extensively studied in the TE field ([@B112]).

Most of the materials so far outlined in this section can be processed into fibres employing strategies explained in the next section. Thermoplastics have also been applied to cTE, mostly as fibrous scaffolds. Examples include poly-ε-caprolactone (PCL), ([@B295]) or elastomers like poly (glycerol-sebacate) (PGS) ([@B137]). Conductive polymers have only recently began to be applied to the field, though some of the most remarkable examples have not incorporated the use of cells and would therefore not qualify as engineered tissues ([@B172]; [@B127]). Finally, given the low mechanical properties displayed by most hydrogels, composite fibre-reinforced materials are also being developed, ([@B18]) with some examples explained in the following section.

Maturation Stimuli {#S3.SS3}
------------------

Cells derived from hPSC are immature (see [@B128] for a review). Although not the direct focus of this work, neonatal myocytes, which are another cell source commonly employed, also suffer from this drawback. cTE has long been aware of this limitation and has applied three main stimuli, namely physical, mechanical and electrical, and combinations thereof [@B214] and [@B256]. Perfusion is able to improve engineered tissues' properties, as it will boost nutrient access and renewal, as has been shown for neonatal cells ([@B225]) as well as hiPSC-cardiac derivatives ([@B276]). Materials' physical properties (e.g., stiffness) are able to induce maturation features in these CMs, or at least preserve primary CMs from dedifferentiation ([@B4]). In general, most hydrogels are able to replicate the right myocardial-like properties. For example, Feaster and colleagues found that plating hiPSC-CMs on thick Matrigel induced a certain degree of molecular and functional maturation, in comparison to thin, diluted hydrogel coating, which essentially transmits the rigidity of the underlying plastic ([@B72]). Herron et al. employed soft (albeit supra-cardiac) substrates and compared them with glass in their capacity to influence hiPSC-CMs, with a significant effect on maturation, showing improvement in the expression of Na and K channels, as well as on the degree of binucleation, cell cycle exit and hypertrophy ([@B101]). Although not purely based on engineered tissues, they and others give proof of the crucial role stiffness plays in cardiac maturation.

Mechanical stimulation has a leading role in cardiac development and aging ([@B96]; [@B244]). It can be isometric, isotonic or auxotonic ([@B158]). In isometric stimulation, the construct is preloaded and must exert force against a static load. In isotonic stimulation, a device will cyclically exert active elongation on the engineered tissue. Finally, auxotonic stimulation occurs when the myocardial tissue has to contract against a resilient load. In principle, the auxotonic mode confers a more physiological stimulation, although all three are reported to deliver maturation upon engineered myocardium ([@B89]; [@B161]; [@B233]; [@B271]). Although the exact mechanisms by which mechanical stimulation matures the cardiac engineered tissue are not known in depth, it is presumed that they will operate by the same ones occurring during cardiac development or physiologic hypertrophy ([@B194]). After all, being a striated muscle, the myocardium can undergo hypertrophy if exercised ([@B140]).

As an electro-sensitive organ, the heart can be stimulated by electrical pulses, which can help maintain its function *ex vivo* ([@B285]). Electrical stimulation is known to have a relevant effect on hPSC-CM differentiation and maturation. Over 20 years ago, Sauer et al. established a relationship between this stimulation and mouse ESC differentiation to CM (EB method). They showed the effect was at least partly mediated by reactive oxygen species (ROS) generation and NF-κB, and could be replicated by ROS from H~2~O~2~ incubation ([@B237]). Serena et al. analysed the effects of the type of electrode and stimulation length on CM differentiation via the EB method from hESC, finding a role for ROS, though the effect on the efficiency of differentiation was not determined ([@B242]). Hernández et al. employed brief (5 min) electrical stimulation, of hiPSC-EBs, finding an increase in the percentage of cardiac differentiation (% of beating EBs) after 14 days ([@B100]). However, the use of the EB method complicates findings, as the effect could also be mediated by other cell types within the EB. Electrical stimulation has also been shown to enhance hPSC-CM maturation at the gene expression and functional levels (Ca transients), as well as promoting the ventricular phenotype ([@B48]). Reasoning that exogenous electrical stimulation would act as an artificial pacemaker, Richards and coworkers evaluated the implementation of electrically conductive silicon nanowires in hiPSC-derived cardiac spheroids, showing that it was able to improve CM-to-CM communication (measured by staining for Connexin 43 and N-cadherin) and structural quality, though some of these quantifications might nowadays be regarded as debatable ([@B226]). The cTE field has implemented electrical stimulation to cardiac constructs with success. The group of Gordana Vunjak-Novakovic pioneered work in this area, showing the enhanced of contraction (synchronicity) and structure (alignment, ultrastructure) on neonatal rat CMs seeded on Ultrafoam collagen sponges and Matrigel ([@B224]). The group developed stimulation protocols as well as bioreactors, ([@B263], [@B262]; [@B170]) which have influenced the whole field. The group of Milica Rasidic built hPSC-based cardiac tissues by embedding hPSC-dissociated EBs in collagen type I and Matrigel. After electrical stimulation, they showed an increased myofibril ultrastructural organisation and improved function (conduction velocity and Ca handling properties) as compared to non-stimulated controls ([@B200]).

Finally, some remarkable advances have been made when combining electrical and mechanical stimulation. Ruan et al. generated collagen-based cardiac engineered tissues containing hPSC-CMs, which were subjected to electromechanical stimulation and compared to static stretch or no stimulus. Results showed a positive Frank-Starling effect (increased force production with increased preload), a less negative force-frequency relationship (increased force production with increased pacing frequency) and maximum stress generation for the electromechanical stimulation group, which was correlated with increased expression of RYR2 and SERCA2, thus supporting the use of combined stimulation for enhanced maturation ([@B233]). The group of Dr. Zimmermann employed auxotonic stimulation delivered through stretchers in combination with electrical pacing at 0, 2, 4, or 6 Hz ([@B89]). Results on tissues generated with collagen and neonatal rat cells showed that the 4 Hz regime was able to generate tissues with a physiological and positive force-frequency and enhanced functionality. Also, the presence of T-tubules was demonstrated. Finally, the group of Prof Vunjak-Novakovic generated hiPSC-CM-based collagen tissues on flexible stretchers (auxotonic mechanical stimulation) and supplied no stimulation (control), 2 Hz and 0.33 Hz/day progressive increase over 2 weeks ('intensity training'). Their results demonstrated the effectiveness of this strategy, as shown by a physiological sarcomere length, increased density of mitochondria, T-tubules, a more mature metabolism and functional improvements at the level of Ca cycling and a positive force-frequency relationship ([@B231]).

Fabrication Strategies {#S3.SS4}
----------------------

Materials confer cTE with significant options, not only due to the available range, but also through the application of different fabrication modalities, which can deliver different properties out of the same starting material. For example, collagen can be mould-casted, ([@B89]) extruded, ([@B8]) or bioprinted, ([@B152]) and the resulting properties will vary widely, with casted and bioprinted collagen having a stiffness in the range of kPa, whilst the extruded film will be significantly stiffer (MPa). In addition, structure will also differ. 3D printing and bioprinting have no doubt revolutionised our capacity to engineer cardiac tissues, however, other technologies can provide relevant features. The following paragraphs outline some of the most employed strategies, classified depending on their capacity to produce a controlled architecture ([Table 3](#T3){ref-type="table"}).

###### 

Summary of fabrication methods, advantages and disadvantages.

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
                                                         Fabrication technique                                        Advantages                                                Disadvantages
  ------------------------------ ----------------------- ------------------------------------------------------------ --------------------------------------------------------- -----------------------------------------------------------------
  No true architecture control   Mould casting           Mould casting ([@B120])                                      -- Simplicity and cost\                                   -- Lowest architectural control\
                                                                                                                      -- High cell survival\                                    -- Limited thickness
                                                                                                                      -- Range of compatible materials\                         
                                                                                                                      -- Mechanical properties\                                 
                                                                                                                      -- Scale up feasible                                      

                                 Pore-forming            Solvent Casting, Particle Leaching, Cryogelation ([@B120])   -- Control of pore size\                                  -- Use of organic solvents\
                                                                                                                      -- No specialised equipment\                              -- Limited scaffold thickness\
                                                                                                                      -- Cost                                                   -- Mechanical properties\
                                                                                                                                                                                -- Time consuming leaching\
                                                                                                                                                                                -- Limited pore architecture

                                 Electrically produced   SE ([@B157])                                                 -- Nanometer features\                                    -- Use of organic solvents\
                                                                                                                      -- Range of compatible materials\                         -- Limited scaffold thickness\
                                                                                                                      -- Scaling up feasible\                                   -- Usually produces high stiffness substrates\

                                 Textile-\               Weaving, Braiding, Knitting ([@B3])                          -- Simple\                                                -- Specialised equipment (cost)\
                                 based                                                                                -- Scaling up feasible\                                   -- Not widespread\
                                                                                                                                                                                -- Limited porosity

  True architecture control      Build & seed            SLA ([@B177])                                                -- High architectural control\                            -- Only photosensitive polymers\
                                                                                                                      -- Self-supporting process\                               -- Remove supporting materials\
                                                                                                                                                                                -- Use of UV light\
                                                                                                                                                                                -- Toxicity of photoinitiator\
                                                                                                                                                                                -- Specialised equipment (cost)

                                                         SLS ([@B173])                                                -- No solvents required\                                  -- High temperature\
                                                                                                                      -- High architectural control\                            -- Materials in powder form\
                                                                                                                      -- Self-supporting process\                               -- Rough surface\
                                                                                                                      -- Range of compatible materials                          -- Specialised equipment (cost)

                                                         MEW ([@B32])                                                 -- No solvents required\                                  -- Limited thickness\
                                                                                                                      -- Control over porosity, pore size and fibre diameter\   -- Range of available material\
                                                                                                                      -- High architectural control                             -- Specialised equipment (cost)\

                                                         FDM ([@B191])                                                -- No solvents required\                                  -- Restricted to materials with good melt viscosity properties\
                                                                                                                      -- Speed of printing\                                     -- High temperature\
                                                                                                                      -- Good reproducibility                                   -- Filament required\
                                                                                                                                                                                -- Limited resolution

                                 Bioprinting             LGDW, LIFT, BioLP ([@B144]; [@B80]; [@B109])                 -- Range of cells/biomaterials\                           -- Low cell viability\
                                                                                                                      -- Single cell resolution\                                -- Limited 3D structure\
                                                                                                                      -- Precise cell printing                                  -- Time consuming

                                                         3DbioP ([@B313])                                             -- Range of cells/biomaterials\                           -- Weak structural support\
                                                                                                                      -- High cell viability\                                   -- Specialised equipment\
                                                                                                                      -- Process at room temperature                            -- Multimaterial printing expensive (multinozzle)
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

SE, Solution electrospinning; LGDW, Laser-guided direct writing; LIFT, Laser Induced Forward Transfer, BioLP, Bio-laser Printing; 3DbioP, 3D bioprinting; SLA, Stereolithography; SLS, Selective laser sintering; MEW, Melt Electrospinning Writing; FDM, Fused deposition modelling.

### Techniques With No True Architecture Control {#S3.SS4.SSS1}

#### Mould casting {#S3.SS4.SSS1.Px1}

Probably the simplest and most widely employed fabrication mode, requires the generation of a mould of the desired shape, and is the fabrication technique of choice in many biomedical-based laboratories, where other methods could not be implemented due to lack of expertise or specific equipment. It does not provide much control over the resulting architecture, but can be combined with others, like porogen leaching, to add specifically selected features to the resulting tissue. The first reports on engineered cardiac tissues by Thomas Eschenhagen and coworkers in the late 1990s were developed by mould-casting a mixture of chick embryonic CMs embedded in a collagen solution. This was allowed to gel between two Velcro-coated glass tubes. The resulting tissues, later termed engineered heart tissues (EHTs), could be cultured *in vitro* and maintained over several days, responded to electrical stimulation, displayed a positive Frank-Starling relationship, were sensitive to levels of extracellular calcium, and could be modified with viral vectors ([@B70]; [@B320]).

Since then, the technology has evolved enormously. It was expanded to neonatal rat cells, ([@B322]) and refined, with the possibility of fabricating more complex and thicker EHTs, which functioned synchronously ([@B321]). These stacked EHTs also showed promise as a therapy when transplanted in a rat model of infarction. EHTs have been employed by the groups of Eschenhagen and Zimmermann, either fibrin- or collagen type I-based, to study the effect of chronic stretch on CM hyperthrophy, ([@B74]) as a disease model of hypertrophic cardiomyopathy, ([@B255]) or to analyze the effect of electrical stimulation ([@B104]). EHT technology has greatly benefited from the implementation of hPSC-derived cells, as the findings, models and application have gained greater impact, be it as a drug testing platform ([@B64]), an *in vitro* tool to study cardiac stimulation, ([@B89]) or as a potential myocardial regenerative therapeutic ([@B289]; [@B266]). The Bursac group has also employed mould casting of rat and human (hiPSC-derived) cells to engineer cardiac tissues and explore different strategies to mature them *in vitro* ([@B114]). They applied this strategy to fabricate tissues up to human scale, though thickness was limited by nutrient and oxygen diffusion. When assayed in a rat model of disease, their cardiopatches retained integrity after 3 weeks, showing extensive vascularisation by host-derived vessels and maintaining electrical activity, although they did not functionally integrate with the endogenous myocardium ([@B245]). The team of Milica Radisic employed PDMS moulds to form engineered cardiac tissues around a surgical suture, composed of hPSC-derived cardiac cells, collagen type I and 10% Matrigel ([@B200]). By employing electrical stimulation, through carbon rods immersed in the culture medium, they were able to drive the hPSC-CMs towards a more mature phenotype and functionality. This system was later applied also to drug testing ([@B73]). Finally, one of the most advanced pieces of evidence for hPSC-CM maturation *in vitro* was provided by the group of Gordana Vunjak-Novakovic, as explained in the previous section ([@B231]). They employed a 3:1 mixture of hPSC-CMs and dermal fibroblasts embedded in a fibrin matrix, cast into wells where flexible PDMS posts were also included. These conferred pre-tension on the generated engineered myocardium, thus adding physiological-like auxotonic stimulation ([@B167]). A set of custom-made carbon electrodes delivered electrical stimulation. The resulting bioartifical myocardium displayed adult-like gene expression profiles, ultrastructural features such as M-bands and T-tubules, as well as oxidative metabolism and mature functionality. In summary, although mould casting cannot generate fine features, it is one of the most widely applied and highly evolved methods to obtain human mature cardiac tissue, and the one closest to translation.

#### Macro-to-micro pore-forming strategies {#S3.SS4.SSS1.Px2}

Cryogelation, based on freeze drying, is a common preservation strategy that is also applied to TE. The pre-crosslinked material is subjected to freeze-thawing cycles, which induces ice crystal formation. These crystals act as porogens, to be removed when pressure is decreased and the solvent sublimated. In general, pores are well inter-connected, as demonstrated early on by O'Brien and colleagues for collagen-glycosaminoglycans scaffolds ([@B201]). In addition, varying conditions make it possible to modulate material properties, as shown by [@B141]. In combination with gas foaming, Dattola et al. fabricated a poly(vinyl) alcohol scaffold with pores within the size of CMs, and Young's Modulus similar to that of the native cardiac ECM. These substrates are able to support the growth and cardiac differentiation of hiPSC, albeit at apparently low rates as demonstrated by the immunostaining for cardiac proteins ([@B56]).

Gas foaming has also been extensively applied to TE, though its use within the cardiac field is not extensive. This technique relies on the formation of bubbles, either by adding exogenous agents such as sodium bicarbonate or through the inclusion of enzymatic-driven reaction in the fabrication process ([@B189]). As the solution polymerises, these bubbles are trapped inside. In consequence, the choice of foaming agent is crucial for the later survival of cells. Although relatively simple to implement, this technique provides no control over the degree of interconnection between the formed pores or their directionality.

Porogen templating is based on the inclusion of salt crystals in the pre-polymer solution. Similar to freeze drying, these crystals will act as templates, creating an empty space (pore) when the particles are leached out, in most cases by dissolving in aqueous solution, weak bases or heating, ([@B265]) with sodium chloride being one of the most frequently employed porogens. On the down side, limitations are related to low architectural control and suboptimal processing of porogens, which might compromise biocompatibility as well as mechanical properties. Salt leaching has not been as widely employed in cTE as in other areas. Ganji et al. used table salt as a simple yet efficient way to generate defined pores in polyurethane-based scaffolds where gold nanotubes and nanowires were incorporated, thus combining 3-dimensionality with the additional benefit of electrical conductivity ([@B81]). Biocompatibility tested with H9c2 rat cardiomyoblasts showed a positive effect on cell growth, though no hPSC-derived cells were tested. Other examples have employed porogen templating for the fabrication of porous polysaccharide-based vascular scaffolds and engineered heart valves ([@B150]; [@B169]).

Thermally induced phase separation is based on the use of temperature to induce the de-mixing of a homogeneous polymer solution. The controlled change in temperature prompts the formation of a polymer-rich and a polymer-poor phase, which can be used to obtain an interconnected porous structure ([@B195]). Vozzi et al. synthesised the elastomer polyesterurethane, and used thermal phase separation to create a porous and biocompatible structure, which they functionalised with fibronectin by NHS-EDC chemistry. Although material properties were off the cardiac optimal range (in the order of \> 0.25 MPa), neonatal rat cardiac cells attached and grew on the scaffolds, with specific modulation of gene expression. However, no use of human cells was reported ([@B278]).

#### Electrically produced {#S3.SS4.SSS1.Px3}

Solution electrospinning (SE), on the other hand, was one of the first and most employed fabrication modalities in the field. In this technique, a polymer solution is subjected to a relatively high electric field while it travels towards a collector plate. This electric field causes the polymeric jet to whip, producing very thin fibres of even sub-micron size, that can be collected randomly or in an aligned fashion. For a review see [@B240]. In general, most SE applications produce low thickness mats of (semi-)randomly arranged fibres of different materials, though use of appliances such as a rotating mandrel can increase alignment ([@B95]). Although relying on the use of potentially toxic solvents, SE has the advantage of being open to a wide range of materials, both natural and synthetic ([@B142]).

The concurrent use of SE with hPSC-derived cardiac cells has not been widely explored but some remarkable examples can be found. The group of Onnik Agbulut tested different crosslinking times of a clinical-grade collagen electrospun scaffold for the most suitable conditions for hiPSC-CM culture. The resulting mats had fibres of 0.6-2.2 μm, with pores in the range of 2-3 μm. After no deleterious effects were found after mat implantation in animals, the mats were seeded with hiPSC-CMs (10^6^ per scaffold), and produced a significant benefit when transplanted in a dilated cardiomyopathy model. Importantly, scaffolds were compliant enough to allow the generation of macroscopic contractions by the hiPSC-CMs ([@B122]). Sireesha et al. used a combination of the elastomer poly\[1,8-octanediol-co-(citric acid)-co-(sebacic acid)\] and fibrinogen to produce scaffolds with a sub-micron fibre diameter, whose mechanical properties laid on the upper end of cardiac elasticity (hundreds of kPa) and which showed good biocompatibility with human CMs. However, no further tests in animal models were performed ([@B248]). Khan and co-workers electrospun polylactide-co-glycolide (PLGA) as 50 μm-thick aligned nanofibrous scaffolds, seeded with hiPSC-CM, and compared the outcome versus conventional tissue culture plastic surfaces. Results showed the scaffolds were able to align the CMs, as well as inducing changes at the level of functionality (Ca transients) and gene expression, though the high stiffness of the mats (1-2 orders of magnitude above the cardiac tissue) could have a negative impact ([@B136]). On the other side of the coin, Han et al. assayed the capacity of aligned electrospun mats made of PCL coated with matrigel to induce hiPSC-CM maturation, showing a limited effect at the functional level, but with some differences in gene expression ([@B95]).

Aside from employing different materials or combinations of natural and synthetic polymers, SE offers increased possibilities by modifying the properties of the resulting engineered tissue by combination with nanoparticles or other fabrication technologies. For example, the group of Tal Dvir built on his previous work on the electrospinning of albumin ([@B76]) to increase the anisotropy of the fabricated engineered tissue. To do this, they employed a double strategy: they used laser patterning to create micro-holes and unidirectional grooves, in order to increase mass transport and cell alignment respectively, and they stacked several layers of patterned mats, inspired by the anisotropy found across the ventricular wall. In this fashion, they also modulated the mechanical properties of the layers, getting closer to human myocardial values. They did not, however, test the stiffness of the resulting stacked construct, nor populate it with human cells, using rat neonatal cardiac cells instead ([@B75]). The group of Ali Khademhosseini used poly(glycerol sebacate):gelatin (PG) solution where gelatin-methacryloyl (GelMA)-coated carbon nanotubes had been incorporated to electrospun aligned nanofibrous mats with improved electrical properties, though at the cost of increased stiffness ([@B138]). This is similar to their previous work with GelMA-embedded carbon nanotubes, ([@B247]) with a significant effect on gene expression, structure and functionality, but again no human cells were employed. Walker et al. employed bio-ionic liquids to modulate the electrical properties and adhesion strength of electrospun GelMA scaffolds, assaying their *in vitro* and *in vivo* regenerative potential, though no tissue was constructed ([@B281]). Again, mechanical properties were affected. Recently, the group of Felix Engel used SE to generate fibres combining the conductive polymer polyaniline (PANi) with collagen/hyaluronic acid, producing mats of suitable mechanical and electrical properties. Scaffolds supported the attachment of hiPSC-CMs, which displayed typical striations and contractions. Substrates incorporating PANi induced a faster beating rate on hiPSC-CMs, though this was not further explored ([@B232]). All in all, SE is a very versatile fabrication technique, and this is also increased by the possibility of combining it with other materials and technologies. However, it faces limitations related to the thickness and dimensions of the final construct, as well as long-range alignment capacity.

#### Textile-based fabrication {#S3.SS4.SSS1.Px4}

Historically speaking, weaving is one of the oldest fabrication techniques and many (bio)materials can be processed by knitting, weaving or braiding, ([@B3]) giving rise to new architectures and importantly, mechanical properties unattainable for individual fibres. Curiously, these have not been mainstream in the cTE field, with few studies combining these fabrication methods with hPSC-derived cells. Though their work cannot fully be categorised as textile-based, the lab of Kevin K. Parker employed pull spinning to generate nanofibrous scaffolds composed of PCL/Gelatin over an ellipsoidal mandrel, mimicking the shape of an idealised ventricle. After additional coating with the ECM protein fibronectin, they seeded either neonatal cardiac rat cells or hiPSC-CMs, generating scale-models of the heart with striking functional properties ([@B164]).

### Techniques With True Architecture Control {#S3.SS4.SSS2}

Additive manufacturing, also known as 3D printing, is one of the technological revolutions of this century. It is based on the building of a volumetric object from a computer aided design (CAD), often in a layer-by-layer basis. Broadly speaking, we can distinguish between bioprinting, where cells are also printed, from the build & seed strategies, where the scaffold is first printed and the cells incorporated in a subsequent step, either as a standalone element or embedded in a hydrogel matrix. In any case, the degree of control over the resulting structure is orders of magnitude above what is achievable with the above-mentioned technologies, with the exception of filament dimensions, with SE being able to go into sub-micron diameter, albeit at the expense of thickness and architecture.

#### 3D Build and Seed {#S3.SS4.SSS2.Px1}

In this category we have gathered those additive manufacturing technologies that do not allow the concurrent printing of materials and cells, be it because they employ high temperature, damaging lasers, toxic solvents or for other reasons. This section includes selective laser sintering (SLS), consisting of iteratively spreading layers of powdered materials and fusing it together to achieve the programmed shape, ([@B62]) stereolithography, where a bath with photosensitive resin is selectively cured layer by layer with a UV laser or similar power source, ([@B84]) or fused deposition modelling (FDM), by which the printed polymer is melted and deposited in layers in order to acquire the desired 3D architecture ([@B191]). All these technologies have in common the need to first generate the architecture and in a second step add the biologicals, with the only exception of laser-curable materials in SLS. Although these technologies are in increased demand for the building of prosthetics, personalised solid implants or educational/surgery planning models, ([@B87]) their application to cTE is not widespread, especially in light of the increasing importance of bioprinting techniques (next section).

A special note however must be dedicated to Melt Electrowriting (MEW), a highly specialised additive manufacturing technology ([@B32]). It works on the same basis as SE, where a high voltage is applied between a syringe tip and a grounded collector. In this case however, the polymer is not dissolved, but melted. The superior stability of the jet allows a highly controlled deposition of fibres, which solidify in-flight or shortly upon collection. These, although bigger in diameter than those from SE, are at least an order of magnitude below what is usually attainable with 3D printing or bioprinting (tens of μm in diameter). The polymer of choice must be melted within the capacities of the printer, which limits the range of the available polymers. Another significant limitation is the achievable 3-dimensionality, which is usually below the mm-range. The groups of Paul Dalton and Dietmar Hutmacher have spearheaded its use ([@B18], [@B17]; [@B105]) and have developed methods to increase the thickness of the MEW scaffolds to almost one cm, but again these are far from mainstream ([@B297]). The groups of Jos Malda and Joost Sluijter have been the first ones to apply MEW to cTE. In their first approach, they MEW-printed the hydroxyl-functionalised polyester, (poly(hydroxymethylglycolide-co-ε-caprolactone) in orthogonal patterns, and seeded them with human cardiac progenitor cells (CPC) embedded in a collagen type I hydrogel. CPCs survived well, with the scaffolds producing a significant alignment ([@B45]). In a further optimisation of the system, Castilho et al. fabricated hexagonally patterned MEW scaffolds with superior compliance, and seeded them with hiPSC-CMs. Their results showed the superior biaxial mechanical properties of the hexagonal designs, and their significant, positive effect on cell alignment and gene expression. Moreover, these scaffolds could be transplanted in a large animal (pig) after passing through a catheter-like tube, paving the way for their future percutaneous transplantation ([@B46]). Finally, an auxetic patch, that is, featuring a negative Poisson ratio, was recently fabricated with MEW, and the conductive polymer polypyrrole *in situ* polymerised on it, with electroconductive properties close to those of the human myocardium ([@B203]).

#### Bioprinting {#S3.SS4.SSS2.Px2}

The capacity to print human tissues on-demand has roused the expectations of scientists, clinicians and patients alike, with a range of modalities available. Laser-assisted bioprinting (LAB) for example, features several methodologies. Laser-induced forward transfer of material/ink (LIFT)([@B144]) allows printing with a single-cell resolution at high densities (up to 10^8^ cells/ml) ([@B80]). However, it requires selected materials to gel relatively fast, which in practice restricts the range of available materials, and can be technically challenging. 2 photon polymerisation is a type of LAB with high spatial resolution (as low as 70 nm) without the need for support structures ([@B109]). Vaithilingam et al. employed this technique to fabricate electroactive 3D architectures by incorporation of multi-walled carbon nanotubes (CNTs). The mechanical properties were however highly deviated from what has been described for human cardiac tissue (GPa range). hiPSC-CMs were able to survive and, after the application of electrical stimulation, a significant effect on sarcomere length was found ([@B273]). There are other printing technologies based on LAB, such as Biological Laser Printing and Laser Guided Direct Writing, ([@B202]; [@B16]) but no reports on these include hiPSC-derived cardiac cells.

Extrusion-based bioprinting is probably the best-known bioprinting method: a bioink containing both cells and the biomaterial is extruded through a nozzle onto a motorised collector. The coordination between the gelation of the bioink and its deposition permits the generation of thick tissues. A range of nozzles, including pneumatic, screw- or plunger-based, as well as inks, is available. However, the material properties of the latter are fundamental, as shear stress generated upon printing highly impacts cell viability ([@B124]). Some strategies, like *in situ* crosslinking of the bioink immediately prior to its deposition, ([@B208]) are being developed to overcome these and other limitations. Extrusion-based bioprinting has been extensively researched in the cTE field. Jang et al. employed a multi-nozzle printer to generate tissues with 2 decellularised cardiac ECM-based bioinks reinforced with a thermoplastic (PCL) backbone. One of the bioinks contained human CPCs (c-kit-positive), and the other mesenchymal stem cells (MSC) and pro-angiogenic factors (VEGF). The application of this patch in a rat model of disease demonstrated a rapid vascularisation as well as a significant benefit at the functional and histological levels. However, no new contractile tissue was formed ([@B119]). Zhang and coworkers employed a more advanced strategy, where they used coaxial printing to pattern human umbilical vein endothelial cells (HUVECs) in a ink containing alginate, GelMA and the UV-curable photoinitiator Irgacure. The mixture was quickly crosslinked by CaCl~2~ from the outer sheath, and further gelled by exposure to UV light (for alginate and GelMA respectively) ([@B316]). HUVECs migrated to the outer border of the printed structures, forming 3D vessel-like structures over a period of 15 days, after which neonatal rat CMs were added to complete the tissue. Izadifar et al. explored varying the electrical properties of the generated tissues by incorporating alginate-coated carbon nanotubes (CNT) to methacrylated collagen. The system displayed as expected enhanced electrical properties, once more at the expense of becoming stiffer, though within acceptable values, and was able to support the growth of human coronary artery endothelial cells. No CMs were employed ([@B113]). Maiullari and coworkers applied a different version of extrusion printing termed microfluidic printing, to generate vascularised engineered tissues combining HUVECs and hiPSC-CMs ([@B165]). The bioartificial myocardium was fabricated with a bioink combining alginate for a rapid crosslinking, and polyethylene glycol (PEG) monoacrylate-fibrinogen, for UV-curing and cell adhesion. These tissues were tested *in vivo*, were the presence of vascular cells was able to promote integration with the recipient vascular system. Zhu et al. formulated a bioink with capacity to electrically influence neonatal rat CMs by incorporating gold nanorods in GelMA. Thick constructs were generated, although cell viability was below 80% in most cases. This is extremely relevant if we take into account that CMs are non-proliferative cells, so no re-growth is likely to occur ([@B319]).

Freeform embedding of suspended hydrogels (FRESH) is one of most exciting 3D bioprinting methods ([@B103]). Here, the biomaterial ink or bioink of choice is printed within the support of another hydrogel serving as a temporary support. Noor and co-workers developed a personalised hydrogel ink from human decellularised omental tissue, which could be printed into complex structures using FRESH. They used it in combination with hiPSC which they differentiated within the matrix into beating, perfused cardiac mini-tissues ([@B198]). Lastly, the Feinberg group used FRESH to accurately (20 μm resolution) 3D print different components of the human heart with collagen, including a model of the left ventricle on the scale of the neonatal organ, incorporating hESC-CMs ([@B152]). These engineered tissues displayed synchronised functional activity.

Finally, some the applications build tissues without the use of biomaterials. This includes the additive manufacturing with spheroids, as demonstrated by Arai et al., where they combined commercially available hPSC-CMs with HUVECs and dermal fibroblasts to generate the spheroids, organised in a tubular 3D structure with a bioprinter ([@B7]). However, the authors used a needle array to provide initial transient support for their structures, which in the end played the role of a scaffolding material. Recently, Ayan et al. reported a novel strategy, termed aspiration-assisted bioprinting, relying on the aspiration of 3D spheroids and their precise deposition in 3D. This could also be combined with FRESH, but no use of hiPSC-derived cardiac cells was reported ([@B9]).

Clinical Translation of hPSC-Based cTE Strategies {#S4}
=================================================

Survival post-cardiac ischemia has raised with advances in the cardiology and cardiovascular surgery areas, as well as through the development of new drugs in the last decades. This includes the application of reperfusion by percutaneous coronary intervention, anticoagulants and antithrombotics, amongst others. Though cTE has potential to address different cardiac conditions, its main activity has been directed towards the loss of viable myocardium by supplying new one, engineered in the lab.

In stark contrast to the short time elapsing between the first reports on regenerative medicine with adult stem cells and their first in-human application (reviewed in [@B12]) cTE with hPSCs has scarcely reached the clinical arena. Be it because both scientists and clinicians have learnt from past experiences or because translation presents additional complications, ([@B58]; [@B85]; [@B133]) clinical application is yet to become a reality. The technology faces challenges in the area of regulation, where reprogrammed cells under GMP-conditions are not widely derived, in logistics, with the size of engineered tissues in most instances requiring open chest surgery, and in economic terms. However, progress is being made. Tiburcy et al., created an engineered human myocardium with advanced structural and functional maturation by combining hPSC-derived cells with collagen type I ([@B266]). Their work, standing on the shoulders of decade-long progress, ([@B322], [@B321]) demonstrated the building of human-scale relevant tissues (3.5 × 3.4 cm, containing 40 million CMs) under defined conditions and their pre-clinical safety assessment in rats, though no large animal testing was performed. The group of Prof Bursac applied dynamic culture conditions to improve the maturation of a patch formed from hiPSC-derived cardiac cells in a fibrin matrix. Although they achieved human adult-like electrical properties (e.g., conduction velocity) and formed large grafts when transplanted into rodents, the use of matrigel in the forming mixture precludes further translation ([@B245]; [@B115]). In addition, myocytes were mostly randomly arrayed, which added to the low thickness of the grafts precludes any efficient and substantial force generation, and therefore makes providing contractile support to diseased hearts difficult.

Menasche et al. performed the first clinical case of an hPSC-based patch in 2015, transplanting a 20 cm^2^ fibrin-based tissue. This patch contained 4 million hESC-derived Isl^+^ SSEA1^+^ CPCs and was implanted epicardially in a 68-year-old patient with advanced heart failure. Concomitant to the implantation of the patch, a coronary artery bypass was also performed. After 3 months, the patient had better symptoms, and there was improved evidence in the echocardiogram too (form akinetic to moderately hypokinetic). Moreover, no adverse effect was observed ([@B180]). This was part of the first clinical trial carried out with six patients suffering from advanced IHD (NCT02057900), called ESCORT. The aim of the trial was to demonstrate the safety of the patch at 1 year. All patients improved symptomatically, with four showing an increased systolic motion. One died early in the post-operative period from treatment-unrelated comorbidities and another after in 22 months due to heart failure ([@B181]).

Japan has made huge efforts to spearhead research in the hiPSC field, and has one of the most streamlined regulatory frameworks (see [@B55] for a comment). It has recently started the first clinical trial of hiPSC-CM transplant in ischemic heart dysfunction. The study will deliver 100 million hiPSC-CMs in the form of a cell sheet of 4 × 5 × 0.1 cm ([@B132]). The aim of the study is to evaluate efficacy and safety of the treatment in a total of 10 patients ([@B54]).

Overall, clinical applications of hPSC-based cardiac engineered tissues, though scarce, are starting to emerge. However, the scientific and logistic/economic concerns mentioned above need addressing further before any of these technologies reach the clinical arena.

Conclusion and Outlook {#S5}
======================

The capacity to fabricate human myocardium in the laboratory is no longer restricted to science fiction. Recent breakthroughs such as cell reprogramming and 3D (bio)printing have shifted the question from 'Can we do it?' to 'How do we want to do it?'. However, lessons from its predecessor in the area of regenerative medicine should teach us the value of caution. Crucial questions remain, some of which include the following:

\-*What are the most suitable components for building an engineered myocardium?* Of course, this absolutely depends on the application/pathology we are targeting. If the objective is to reconstruct the post-disease myocardium, especially in cases when muscular mass has been loss (as IHD), this will require new CMs, alongside new vessels and support cells. Although not supplying new CMs might still be beneficial, it will not regenerate the tissue to pre-disease levels. So far, only hPSCs can produce the required cells in sufficiently large amounts, and whether it is better to use fully differentiated cells or progenitors is still an open question. Regarding the ECM-mimics, the current state can seem confusing. All reported (bio)material formulations seem to provide a benefit ([Table 2](#T2){ref-type="table"}). It is plausible that the most important factor is for the material to recapitulate the mechanical environment of cardiac tissue long enough for delivered cells to build their own structure. Also, although collagen type I has repeatedly been positioned as being the main component of the cardiac ECM, this does not account for all its mechanical capacities, nor it is as abundant as the levels supplemented in engineered tissues. Probably, cost and translation capacity will have much to say here. Lastly, regarding the fabrication mode, though 3D bioprinting has captivated both scientists and the wider public, its actual ability to deliver tissues able to withstand the mechanical forces in play in the human myocardium is far from optimal in most cases. Fibre reinforcement might be a solution to this, but remains to be fully tested in a human scale. In addition, recent technical developments such as 4D printing or cyborganics will certainly widen the scope of possibilities at hand ([@B260]; [@B204]).

-- *How is translation going to happen?* The hurdles are significant, ([@B58]; [@B85]) not only due to the use of genetically modified cells (hiPSCs), exogenous materials and complex equipment, but also because in order to attain sufficient functional capacity, it is likely that some lengthy period of *in vitro* electromechanical maturation must be implemented. Also, no standard equipment currently exists to apply this to a human-scale tissue. In this area, it is crucial that biomedical researchers work alongside lawmakers. Cell therapy mostly relied on an autologous application of a non-cultured material, which smoothened its approval. Tissue engineering applications based on hiPSC products are highly promising but are impeded by stringent regulations. Japan has spearheaded hiPSC translation as a national flagship ([@B10]). Although some consider this too loose, it is clear that unless scientists provide a clear direction and get themselves involved in depth in the regulatory process, advances will be limited.

-- *Will costs be sensible?* hiPSC culture and differentiation are expensive. Additive manufacturing is expensive. GMP-grade materials are expensive. hiPSC line derivation costs between €4000-8000 depending on the provider, multi-nozzle 3D bioprinters are usually budgeted above €30000, and some medical-grade materials as human collagen type I are prohibitive (\> €200 per 100 μg). Highly trained personnel costs need to be added on top of this, as well as the cost of hiPSC expansion and differentiation. The cost of a heart transplant in the United States is above \$150000 (including 120-day medical care), with Left Ventricular Assist Devices (LVADs), employed for patients with end stage heart failure as a bridge to transplant (and now trialled as destination therapy) are estimated to cost even more (see [@B183] for a concise review). If economic issues are not addressed from day one, we run the risk of ending up with a highly effective therapy only that very few people can pay for. Large-scale production of hiPSC-derived cells has been demonstrated and will no doubt help decrease costs ([@B1]; [@B94]; [@B38]). Strategies to induce hiPSC-CM division would significantly improve the economics.

-- *Will the new therapy be safe?* hPSCs have been marred by concerns related to persistence of pluripotent cells after differentiation and the subsequent risk of teratoma formation. But also, the new tissue must conform to the host's electrical activity. Again, lessons from Cell Therapy call for caution ([@B179]). Advanced genomics and other analysis tools not available 10 years ago will significantly enhance the safety analysis and help researchers and clinicians along the way ([@B284]).

-- *Are the aims achievable?* The objective of cTE is to generate new human myocardium whose properties and functionality are similar to its natural counterpart, but that might not be achievable within a sensible timeframe. Human cardiac maturation advances significantly after birth but continues throughout the first decades of life. Current advanced methods for maturation, like those based on electromechanical stimulation, do not achieve anything even close to adult properties. However, it is plausible that only a minimal maturity is needed in order to avoid lethal arrhythmias, as hPSC-CMs are reported to undergo maturation after transplantation in the heart ([@B126]).

-- *What is the state of non-therapeutic applications?* Though the aim of cTE within regenerative medicine is directed towards treatment, bioartificial human myocardium is becoming increasingly relevant with respect to other applications such as disease modelling and drug testing ([@B280]; [@B246]), where the scale of the fabricated tissues is not an issue. In drug testing, the CiPA initiative has already pointed to the relevance of hiPSC-CMs, ([@B182]) especially given cardiac side effects are one of the main reasons for drug withdrawal, and there is no primary source of human CMs available ([@B151]). Current efforts have already proven the capacity of cTE-based systems to better recapitulate physiological human drug response \[reviewed in [@B126] and [@B182], or to generate chamber-specific microtissues ([@B317])\]. Translation towards industrial and clinical testing is envisioned to be more straightforward and immediate.

As can be seen, the challenges ahead are not minor. However, humankind has never been closer to achieving success in tissue fabrication. Whole functional heart generation in the laboratory, though frequently dreamt of, is still not achievable, as severe physiological and technical roadblocks remain in place. Challenges include ensuring adequate vascularisation, electromechanical coupling over long distances, atrioventricular delay, autonomous nervous system innervation or designing materials both biocompatible but capable of supporting the strong mechanics of a whole heart, amongst others. At this extraordinary moment, it is crucial for scientists, clinicians, and lay people to stay focused and deliver.
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